Rachna Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rachna Singh has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Anjna Kumari
Department of Microbial Biotechnology, Panjab University, Chandigarh 160014, India
8 shared publications- Pallab Ray
Postgraduate Institute of Medical Education and Research
7 shared publications - Arunaloke Chakrabarti
Department of Medical Microbiology Postgraduate Institute of Medical Education and Research Chandigarh India
6 shared publications Mahaldeep Kaur
Present address: Laboratory of Clinical Immunology and Microbiology, Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
6 shared publicationsMeera Sharma
Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India
5 shared publicationsAnayata Sharma
Department of Microbial Biotechnology, Panjab University, Chandigarh - 160014, India
4 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (7) , 002184
Role of zinc in growth, stress response and virulence gene expression of pathogenic Mucorale Rhizopus arrhizus
Introduction. During the coronavirus disease 2019 (COVID-19) pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation. Several risk factors were implicated in the emergence of COVID-19-associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19-associated glycaemic imbalance. Gap statement. Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of CAM, but experimental evidence remains limited. Aim. This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis. Methodology. The effect of zinc supplementation (5 to 150 µM) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in Roswell Park Memorial Institute -1640 medium. Morphological changes were visualized by scanning electron microscopy. Gene expression and intracellular zinc levels were determined by RNA sequencing and inductively coupled plasma mass spectrometry, respectively. The cytotoxic potential of R. arrhizus pre-cultured with and without zinc supplementation was assessed in the human embryonic kidney 293 cell line. Results. Zinc supplementation promoted R. arrhizus growth in a concentration-dependent manner, with the effect being particularly pronounced under less-favourable conditions, such as alkaline conditions resembling the nasal pH of diabetics. The results further suggested a zinc-specific effect: supplementation with another trace element (copper) suppressed R. arrhizus growth, and the zinc chelator (1,10-phenanthroline) dose-dependently abrogated the zinc-induced growth enhancement. Exposure to zinc increased the metabolic activity, and partly alleviated cell-wall and oxidative stress. Susceptibility to amphotericin B and posaconazole was unchanged. Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein. R. arrhizus cytotoxicity was also significantly enhanced upon pre-culturing with zinc supplementation. Additionally, zinc augmented the growth/metabolism of several other Mucorales but not Aspergillus fumigatus and Candida albicans . Conclusion. Zinc supplementation promotes mucoralean growth, increases cytotoxic potential and enhances the expression of key virulence factors, including mucoricin and iron transporters. The findings contribute experimental evidence supporting the proposed association of zinc over-availability with the emergence of CAM.
- 14 July 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (7) , 002184
Open AccessRole of zinc in growth, stress response and virulence gene expression of pathogenic Mucorale Rhizopus arrhizus
Introduction. During the coronavirus disease 2019 (COVID-19) pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation. Several risk factors were implicated in the emergence of COVID-19-associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19-associated glycaemic imbalance. Gap statement. Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of CAM, but experimental evidence remains limited. Aim. This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis. Methodology. The effect of zinc supplementation (5 to 150 µM) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in Roswell Park Memorial Institute -1640 medium. Morphological changes were visualized by scanning electron microscopy. Gene expression and intracellular zinc levels were determined by RNA sequencing and inductively coupled plasma mass spectrometry, respectively. The cytotoxic potential of R. arrhizus pre-cultured with and without zinc supplementation was assessed in the human embryonic kidney 293 cell line. Results. Zinc supplementation promoted R. arrhizus growth in a concentration-dependent manner, with the effect being particularly pronounced under less-favourable conditions, such as alkaline conditions resembling the nasal pH of diabetics. The results further suggested a zinc-specific effect: supplementation with another trace element (copper) suppressed R. arrhizus growth, and the zinc chelator (1,10-phenanthroline) dose-dependently abrogated the zinc-induced growth enhancement. Exposure to zinc increased the metabolic activity, and partly alleviated cell-wall and oxidative stress. Susceptibility to amphotericin B and posaconazole was unchanged. Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein. R. arrhizus cytotoxicity was also significantly enhanced upon pre-culturing with zinc supplementation. Additionally, zinc augmented the growth/metabolism of several other Mucorales but not Aspergillus fumigatus and Candida albicans . Conclusion. Zinc supplementation promotes mucoralean growth, increases cytotoxic potential and enhances the expression of key virulence factors, including mucoricin and iron transporters. The findings contribute experimental evidence supporting the proposed association of zinc over-availability with the emergence of CAM.
- 4 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 132-142
Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis
Background: Mucormycosis is a life-threatening invasive fungal infection. Current diagnosis relies on insensitive techniques with prolonged turnaround times, underscoring the need for rapid noninvasive diagnostic tools. The current study aimed to identify the antigens of Rhizopus arrhizus that can facilitate serodiagnosis of mucormycosis and assess their diagnostic potential in patients. Methods: This was a 2-stage systematic study combining antigen discovery and clinical validation. Using immunoproteomics, we identified immunoreactive protein spots in R. arrhizus secretory extract, using pooled serum samples from 6 patients with mucormycosis. We performed liquid chromatography–tandem mass spectrometry (LC-MS/MS) to characterize the most reactive spot. Next, we developed an indirect enzyme-linked immunosorbent assay using purified protein and evaluated its diagnostic performance in 92 patients with mucormycosis and 41 controls (22 with other mold infections and 19 with diabetes mellitus alone). Participants were randomly divided 1:1 into derivation and validation cohorts. Receiver operating characteristic curve analysis identified optimal cutoff values. Results: Immunoproteomics identified 3 immunoreactive protein spots (70, 45, and 30 kDa) in crude extract. The most reactive 70-kDa spot was identified as Rhizopus-specific glucoamylase (RSG) by LC-MS/MS and confirmed with specific anti-Rhizopus glucoamylase antibody. In the derivation cohort (46 patients with mucormycosis and 11 controls), the area under the receiver operating characteristic curve for anti-RSG immunoglobulin (Ig) G was 0.933. In the validation cohort, anti-RSG IgG achieved 76.1% sensitivity (95% confidence interval, 61.2%–87.4%) and 100% specificity (71.5%–100%). The assay also detected antibodies in 85.1% of culture-negative but microscopy-positive cases and in 87.5% of mixed fungal infection cases. Conclusions: RSG is a potential biomarker for diagnosing mucormycosis. Anti-RSG IgG shows strong diagnostic promise and merits prospective multicenter clinical validation.
- 4 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 132-142
Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis
Background: Mucormycosis is a life-threatening invasive fungal infection. Current diagnosis relies on insensitive techniques with prolonged turnaround times, underscoring the need for rapid noninvasive diagnostic tools. The current study aimed to identify the antigens of Rhizopus arrhizus that can facilitate serodiagnosis of mucormycosis and assess their diagnostic potential in patients. Methods: This was a 2-stage systematic study combining antigen discovery and clinical validation. Using immunoproteomics, we identified immunoreactive protein spots in R. arrhizus secretory extract, using pooled serum samples from 6 patients with mucormycosis. We performed liquid chromatography–tandem mass spectrometry (LC-MS/MS) to characterize the most reactive spot. Next, we developed an indirect enzyme-linked immunosorbent assay using purified protein and evaluated its diagnostic performance in 92 patients with mucormycosis and 41 controls (22 with other mold infections and 19 with diabetes mellitus alone). Participants were randomly divided 1:1 into derivation and validation cohorts. Receiver operating characteristic curve analysis identified optimal cutoff values. Results: Immunoproteomics identified 3 immunoreactive protein spots (70, 45, and 30 kDa) in crude extract. The most reactive 70-kDa spot was identified as Rhizopus-specific glucoamylase (RSG) by LC-MS/MS and confirmed with specific anti-Rhizopus glucoamylase antibody. In the derivation cohort (46 patients with mucormycosis and 11 controls), the area under the receiver operating characteristic curve for anti-RSG immunoglobulin (Ig) G was 0.933. In the validation cohort, anti-RSG IgG achieved 76.1% sensitivity (95% confidence interval, 61.2%–87.4%) and 100% specificity (71.5%–100%). The assay also detected antibodies in 85.1% of culture-negative but microscopy-positive cases and in 87.5% of mixed fungal infection cases. Conclusions: RSG is a potential biomarker for diagnosing mucormycosis. Anti-RSG IgG shows strong diagnostic promise and merits prospective multicenter clinical validation.
- Open Access
- 22 November 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (11) , 001929
Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi
Introduction. Mucormycosis is an aggressive, angioinvasive infection associated with high morbidity and mortality. The disease remains difficult to treat, with limited available antifungal drugs. Consequently, there is an urgent need to develop alternate therapeutics against mucormycosis. In an earlier study, we demonstrated that the non-steroidal anti-inflammatory drug diflunisal impacted the actin cytoskeleton and quorum sensing and inhibited the formation of filopodia-/cytoneme-like extensions in Rhizopus arrhizus. Hypothesis. The non-steroidal anti-inflammatory drug diflunisal could exhibit potential antifungal activity. Aim. This study aimed to investigate the plausible antifungal activity of diflunisal against a range of medically important Mucorales and its combination effect with antifungal drugs. Methodology. The antifungal activity of diflunisal against Rhizopus arrhizus, Lichtheimia corymbifera, Rhizomucor pusillus, Cunninghamella bertholletiae, Mucor indicus, Mucor irregularis and Apophysomyces elegans was evaluated by broth microdilution assay. Allied salicylates were also screened. A combination assay with amphotericin B deoxycholate and posaconazole was performed by fractional inhibitory concentration test. Results. Exposure to diflunisal inhibited Rhizopus arrhizus spore germination in a dose-dependent manner. MICs of diflunisal against different Mucorales ranged from 64 to 2048 µg ml−1. Remarkably low levels of diflunisal (0.03–2 µg ml−1), depending on the strain/species tested, improved the antifungal activity of amphotericin B against mucoralean fungi by twofold (ΣFIC ≈ 0.5–0.508; P<0.01). Field-emission scanning electron micrographs further confirmed these observations. MICs of posaconazole were unchanged by this compound. Conclusion. Considering that amphotericin B remains the first-line drug against mucormycosis and exhibits dose-dependent side effects in clinical practice, especially nephrotoxicity, the observed additive interaction at remarkably low, clinically achievable levels of diflunisal demonstrates its potential utility as an adjunct therapy against mucoralean fungi.
- 22 November 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (11) , 001929
Open AccessRepurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi
Introduction. Mucormycosis is an aggressive, angioinvasive infection associated with high morbidity and mortality. The disease remains difficult to treat, with limited available antifungal drugs. Consequently, there is an urgent need to develop alternate therapeutics against mucormycosis. In an earlier study, we demonstrated that the non-steroidal anti-inflammatory drug diflunisal impacted the actin cytoskeleton and quorum sensing and inhibited the formation of filopodia-/cytoneme-like extensions in Rhizopus arrhizus. Hypothesis. The non-steroidal anti-inflammatory drug diflunisal could exhibit potential antifungal activity. Aim. This study aimed to investigate the plausible antifungal activity of diflunisal against a range of medically important Mucorales and its combination effect with antifungal drugs. Methodology. The antifungal activity of diflunisal against Rhizopus arrhizus, Lichtheimia corymbifera, Rhizomucor pusillus, Cunninghamella bertholletiae, Mucor indicus, Mucor irregularis and Apophysomyces elegans was evaluated by broth microdilution assay. Allied salicylates were also screened. A combination assay with amphotericin B deoxycholate and posaconazole was performed by fractional inhibitory concentration test. Results. Exposure to diflunisal inhibited Rhizopus arrhizus spore germination in a dose-dependent manner. MICs of diflunisal against different Mucorales ranged from 64 to 2048 µg ml−1. Remarkably low levels of diflunisal (0.03–2 µg ml−1), depending on the strain/species tested, improved the antifungal activity of amphotericin B against mucoralean fungi by twofold (ΣFIC ≈ 0.5–0.508; P<0.01). Field-emission scanning electron micrographs further confirmed these observations. MICs of posaconazole were unchanged by this compound. Conclusion. Considering that amphotericin B remains the first-line drug against mucormycosis and exhibits dose-dependent side effects in clinical practice, especially nephrotoxicity, the observed additive interaction at remarkably low, clinically achievable levels of diflunisal demonstrates its potential utility as an adjunct therapy against mucoralean fungi.
A novel indirect ELISA for serodiagnosis of mucormycosis using antigens from Rhizopus arrhizus
Background: Due to a delay in diagnosis by conventional techniques and high mortality, the development of a standardised and rapid non‐culture‐based technique is an unmet need in pulmonary, gastrointestinal, and disseminated forms of mucormycosis. Though limited studies have been conducted for molecular diagnosis, there are no established serologic tests for this highly fatal infection.Objective: To develop and evaluate an indirect in‐house enzyme‐linked immunosorbent assay (ELISA) utilising antigens of Rhizopus arrhizus for detecting anti‐Rhizopus antibodies (IgG and IgM) in sera of patients with mucormycosis.Methods: We extracted both secretory and mycelial Rhizopus antigens using standardised protocols. Bradford assay was used for protein quantification. We then standardised an indirect ELISA using R. arrhizus mycelial and secretory antigens (10.0 μg/mL in bicarbonate buffer pH 9.2) for detecting anti‐Rhizopus IgG and IgM antibodies in patient sera. We included patients with mucormycosis, other fungal infections, and healthy controls. Antibody index value (E‐value) was calculated for each patient sample.Results: Asparagine broth culture filtrate utilising 85% ammonium sulphate salt fractionation and mycelial homogenate grown in yeast extract peptone dextrose (YPD) broth precipitated with trichloroacetic acid (TCA) yielded a large amount of good‐quality protein for the assay. We included 55 patients with mucormycosis (rhino‐orbito‐cerebral mucormycosis [ROCM, n = 39], pulmonary [n = 15], gastrointestinal [n = 1]), 24 with other fungal infections (probable aspergillosis [n = 14], candidiasis [n = 10]), and healthy controls (n = 16). The sensitivity of the antibody test for diagnosing mucormycosis ranged from 83.6–92.7% for IgG and 72.7–87.3% for IgM, with a specificity of 91.7–92.5% for IgG and 80–82.5% for IgM. The sera from patients with other fungal infections and healthy individuals did not show significant cross‐reactivity.Conclusion: The detection of anti‐Rhizopus IgG antibody performed significantly better in comparison to IgM‐based ELISA for diagnosing both ROCM (sensitivity of 84.6% vs. 69.2%) and pulmonary cases (86.6% vs. 80.0%). More extensive studies are required to confirm our findings.
A novel indirect ELISA for serodiagnosis of mucormycosis using antigens from Rhizopus arrhizus
Background: Due to a delay in diagnosis by conventional techniques and high mortality, the development of a standardised and rapid non‐culture‐based technique is an unmet need in pulmonary, gastrointestinal, and disseminated forms of mucormycosis. Though limited studies have been conducted for molecular diagnosis, there are no established serologic tests for this highly fatal infection.Objective: To develop and evaluate an indirect in‐house enzyme‐linked immunosorbent assay (ELISA) utilising antigens of Rhizopus arrhizus for detecting anti‐Rhizopus antibodies (IgG and IgM) in sera of patients with mucormycosis.Methods: We extracted both secretory and mycelial Rhizopus antigens using standardised protocols. Bradford assay was used for protein quantification. We then standardised an indirect ELISA using R. arrhizus mycelial and secretory antigens (10.0 μg/mL in bicarbonate buffer pH 9.2) for detecting anti‐Rhizopus IgG and IgM antibodies in patient sera. We included patients with mucormycosis, other fungal infections, and healthy controls. Antibody index value (E‐value) was calculated for each patient sample.Results: Asparagine broth culture filtrate utilising 85% ammonium sulphate salt fractionation and mycelial homogenate grown in yeast extract peptone dextrose (YPD) broth precipitated with trichloroacetic acid (TCA) yielded a large amount of good‐quality protein for the assay. We included 55 patients with mucormycosis (rhino‐orbito‐cerebral mucormycosis [ROCM, n = 39], pulmonary [n = 15], gastrointestinal [n = 1]), 24 with other fungal infections (probable aspergillosis [n = 14], candidiasis [n = 10]), and healthy controls (n = 16). The sensitivity of the antibody test for diagnosing mucormycosis ranged from 83.6–92.7% for IgG and 72.7–87.3% for IgM, with a specificity of 91.7–92.5% for IgG and 80–82.5% for IgM. The sera from patients with other fungal infections and healthy individuals did not show significant cross‐reactivity.Conclusion: The detection of anti‐Rhizopus IgG antibody performed significantly better in comparison to IgM‐based ELISA for diagnosing both ROCM (sensitivity of 84.6% vs. 69.2%) and pulmonary cases (86.6% vs. 80.0%). More extensive studies are required to confirm our findings.
- Open Access
- 6 September 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1280784
Editorial: Research advances in mucormycosis
Editorial: Research advances in mucormycosis
- 6 September 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1280784
Open AccessEditorial: Research advances in mucormycosis
Editorial: Research advances in mucormycosis
- 12 January 2023
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 81
In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms
Klebsiella pneumoniae is an opportunistic pathogen associated with biofilm-based infections, which are intrinsically antibiotic resistant. Extracellular DNA plays a crucial role in biofilm formation and self-defence, with nucleases being proposed as promising agents for biofilm disruption. This study evaluated the in vitro and in vivo efficacy of DNase I in improving the activity of cefotaxime, amikacin and ciprofloxacin against K. pneumoniae biofilms. K. pneumoniae ATCC 700603 and a clinical isolate from catheter-related bloodstream infection were cultured for biofilm formation on microtiter plates, and the anti-biofilm activity of the antibiotics (0.03–64 mg/L), with or without bovine pancreatic DNase I (1–32 mg/L) was determined by XTT dye reduction test and viable counting. The effect of ciprofloxacin (2 mg/L) and DNase I (16 mg/L) was further evaluated in vitro on 1-cm-long silicon catheter segments and in a mouse model of subcutaneous catheter-associated infection. Combination with DNase I did not improve the biofilm-preventive capacity of the three antibiotics or the biofilm-eradicating capacity of cefotaxime and amikacin. The biofilm-eradicating capacity of ciprofloxacin was increased by eight-fold and four-fold in K. pneumoniae ATCC 700603 and clinical isolate respectively with DNase I. The combination therapy caused 99% reduction in biofilm biomass in the mouse model.
- 12 January 2023
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 81
In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms
Klebsiella pneumoniae is an opportunistic pathogen associated with biofilm-based infections, which are intrinsically antibiotic resistant. Extracellular DNA plays a crucial role in biofilm formation and self-defence, with nucleases being proposed as promising agents for biofilm disruption. This study evaluated the in vitro and in vivo efficacy of DNase I in improving the activity of cefotaxime, amikacin and ciprofloxacin against K. pneumoniae biofilms. K. pneumoniae ATCC 700603 and a clinical isolate from catheter-related bloodstream infection were cultured for biofilm formation on microtiter plates, and the anti-biofilm activity of the antibiotics (0.03–64 mg/L), with or without bovine pancreatic DNase I (1–32 mg/L) was determined by XTT dye reduction test and viable counting. The effect of ciprofloxacin (2 mg/L) and DNase I (16 mg/L) was further evaluated in vitro on 1-cm-long silicon catheter segments and in a mouse model of subcutaneous catheter-associated infection. Combination with DNase I did not improve the biofilm-preventive capacity of the three antibiotics or the biofilm-eradicating capacity of cefotaxime and amikacin. The biofilm-eradicating capacity of ciprofloxacin was increased by eight-fold and four-fold in K. pneumoniae ATCC 700603 and clinical isolate respectively with DNase I. The combination therapy caused 99% reduction in biofilm biomass in the mouse model.
- Open Access
- 1 January 2022
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 155 (1) , 73-78
Quorum-sensing effector pyocyanin but not farnesol & acyl homoserine lactone exhibit antibacterial activity
- 1 January 2022
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 155 (1) , 73-78
Open AccessQuorum-sensing effector pyocyanin but not farnesol & acyl homoserine lactone exhibit antibacterial activity
- 30 July 2021
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (8) , 2211-2213
Nasal Microbiota Imbalance as a Contributory Link in the Emergence of COVID-19 Associated Mucormycosis
COVID-19 associated mucormycosis (CAM) is being reported at an elevated frequency and has been declared an ongoing epidemic in India. A huge diabetic population, inappropriate corticosteroid usage and environmental mucoralean spore count, along with COVID-19 associated glycemic imbalance, hypoxemia, increased iron levels, vascular endothelial injury, as well as the immunosuppressive impact are being considered as important risk factors for CAM. The present viewpoint aims to discuss the plausible role of another important facet, the nasal microbiota imbalance, in the emergence of mucormycosis under the prevailing COVID-19 pandemic conditions.
- 30 July 2021
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (8) , 2211-2213
Nasal Microbiota Imbalance as a Contributory Link in the Emergence of COVID-19 Associated Mucormycosis
COVID-19 associated mucormycosis (CAM) is being reported at an elevated frequency and has been declared an ongoing epidemic in India. A huge diabetic population, inappropriate corticosteroid usage and environmental mucoralean spore count, along with COVID-19 associated glycemic imbalance, hypoxemia, increased iron levels, vascular endothelial injury, as well as the immunosuppressive impact are being considered as important risk factors for CAM. The present viewpoint aims to discuss the plausible role of another important facet, the nasal microbiota imbalance, in the emergence of mucormycosis under the prevailing COVID-19 pandemic conditions.